MAP2K1 and colorectal cancer: While the reverse combination (BYL719 anchor drug with siRNA targeting MAP2K1) was not identified as synergistic, this is likely due to redundancy between MAP2K1 and MAP2K2. These results confirmed the ability of the screening methodology to identify known genes involved in colorectal cancer cell viability, and examples of synergistic drug/siRNA phenotypes.